VKTX
VKTX clinical trials: Viking Therapeutics, Inc.
Every trial on ClinicalTrials.gov where Viking Therapeutics, Inc. is the lead sponsor or a listed collaborator, the trials it leads first, each labelled Lead or Collaborator. Phase, status and dates as registered.
- 13
- Trials linked
- 13
- As lead sponsor
- 0
- As collaborator
- 0
- Primary completions as lead sponsor, next 90 days
VKTX on the catalyst calendar · VKTX registry changes
- Primary completion Oct 2028Sponsor estimatePhase 3NCT07868939Oral VK2735 for Weight Management in Adults With Type 2 Diabetes Mellitus Phase 3 (SUNRISE 2)Viking Therapeutics, Inc. · Weight LossRecruitingVKTXLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jul 2028Sponsor estimatePhase 3NCT07868835Oral VK2735 for Weight Management Phase 3 (SUNRISE 1)Viking Therapeutics, Inc. · Weight LossRecruitingVKTXLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Oct 2, 2026Sponsor estimatePhase 1NCT07846033A Phase 1 Study of VK3019 in Overweight and Obese Adults Without ComorbiditiesViking Therapeutics, Inc. · Obese AdultsRecruitingVKTXLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion May 2027Sponsor estimatePhase 1NCT07838740A Phase 1 Study of VK2735 in Obese Adults Without ComorbiditiesViking Therapeutics, Inc. · Obese AdultsRecruitingVKTXLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jul 1, 2027Sponsor estimatePhase 3NCT07104383VK2735 for Weight Management Type 2 Diabetes Phase 3 (VANQUISH 2)Viking Therapeutics, Inc. · Weight LossActive, not recruitingVKTXLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Nov 15, 2017ActualPhase 2NCT02578095Acute Hip Fracture Study in Patients 65 Years or GreaterViking Therapeutics, Inc. · Hip FracturesCompletedVKTXLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jul 1, 2027Sponsor estimatePhase 3NCT07104500VK2735 for Weight Management Phase 3Viking Therapeutics, Inc. · Weight LossActive, not recruitingVKTXLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jun 24, 2025ActualPhase 2NCT06828055VK2735 for Weight Management Phase 2 (Venture Oral Dosing)Viking Therapeutics, Inc. · Weight LossCompletedVKTXLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Nov 4, 2024ActualPhase 1NCT05203237Phase 1 Study to Evaluate the Safety and Tolerability of VK2735Viking Therapeutics, Inc. · Weight LossCompletedVKTXLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Oct 9, 2024ActualPhase 1NCT04973657A Study to Assess the Pharmacodynamics of VK0214 in Male Subjects With AMNViking Therapeutics, Inc. · Adrenomyeloneuropathy Form (AMN) of X-linked Adrenoleukodystrophy (X-ALD)CompletedVKTXLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Feb 27, 2024ActualPhase 2NCT06068946VK2735 for Weight Management Phase 2Viking Therapeutics, Inc. · Weight LossCompletedVKTXLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion May 15, 2023ActualPhase 2NCT04173065A Study to Assess the Efficacy and Safety of VK2809 for 52 Weeks in Subjects With Biopsy Proven NASHViking Therapeutics, Inc. · NASH - Nonalcoholic SteatohepatitisCompletedVKTXLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Mar 26, 2019ActualPhase 2NCT02927184Safety and Tolerability of VK2809 in Patients With Primary Hypercholesterolemia and Non-Alcoholic Fatty Liver DiseaseViking Therapeutics, Inc. · HyperlipidemiaCompletedVKTXLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
Enrollment, interventions and the start and completion dates are locked on 13 rows here. Included with TrialScanner ($9.99 a month) and Signal8 Pro.
Unlock with TrialScanner